This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hanna, N. Articles by Bonomi, P. Search for Related Content PubMed PubMed Citation Articles by Hanna, N. Articles by Bonomi, P. Social Bookmarking                            What's this?

Phase II Trial of Cetuximab in Patients With Previously Treated Non–Small-Cell Lung Cancer

Nasser Hanna, Rogerio Lilenbaum, Rafat Ansari, Thomas Lynch, Ramaswamy Govindan, Pasi A. Jänne, Philip Bonomi

From the Indiana University, Indianapolis; Michiana Oncology/Hematology, South Bend, IN; Mt Sinai Cancer Center, Miami Beach, FL; Massachusetts General Hospital; Dana-Farber Cancer Institute, Boston, MA; Washington University, St Louis, MO; and Rush Medical College, Chicago, IL

Address reprint requests to Nasser Hanna, MD, 535 Barnhill Dr, RT 473, Indianapolis, IN 46202; e-mail: nhanna{at}iupui.edu

Purpose To determine the efficacy of cetuximab in patients with recurrent or progressive non–small-cell lung cancer (NSCLC) after receiving at least one prior chemotherapy regimen.

Patients and Methods This was an open-label, phase II study of patients with epidermal growth factor receptor (EGFR) –positive and EGFR-negative advanced NSCLC with Eastern Cooperative Oncology Group performance status 0 to 1. Patients received cetuximab 400 mg/m² intravenously (IV) during 120 minutes on week 1 followed by weekly doses of cetuximab 250 mg/m² IV during 60 minutes. A cycle was considered as 4 weeks of treatment and therapy was continued until disease progression or intolerable toxicities. The primary end point was to assess response rate. Secondary end points included an estimation of time to progression and survival.

Results Patient and disease characteristics (n = 66) included EGFR-positive status (n = 60); EGFR-negative status (n = 6); number of prior regimens (one, n = 28; two, n = 27; three, n = 11); male (n = 41); female (n = 25); adenocarcinoma (n = 36); and smoking status (never, n = 13; former, n = 45; current, n = 8). Grade 3/4 toxicities included acne-like rash (6.1%), anaphylactic reactions (1.5%), and diarrhea (1.5%). The response rate for all patients (n = 66) was 4.5% (95% CI, 0.9% to 12.7%) and the stable disease rate was 30.3% (95% CI, 19.6% to 42.9%). The response rate for patients with EGFR-positive tumors (n = 60) was 5% (95% CI, 1.0% to 13.9%). The median time to progression for all patients was 2.3 months (95% CI, 2.1 to 2.6 months) and median survival time was 8.9 months (95% CI, 6.2 to 12.6 months).

Conclusion Although the response rate with single-agent cetuximab in this heavily pretreated patient population with advanced NSCLC was only 4.5%, the disease control rates and overall survival seem comparable to that of pemetrexed, docetaxel, and erlotinib in similar groups of patients.

Supported by a grant from Bristol-Myers Squibb Co.

Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2004, New Orleans, LA; the 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL; and the International Association for the Study of Lung Cancer, July 3-6, 2005, Barcelona, Spain.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Lilenbaum, X. Wang, L. Gu, J. Kirshner, K. Lerro, and E. Vokes Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402 J. Clin. Oncol., September 20, 2009; 27(27): 4487 - 4491. [Abstract] [Full Text] [PDF]

				B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J.-F. Baurain, L. D'Hondt, T. Strauven, C. Chaskis, P. In't Veld, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma Ann. Onc., September 1, 2009; 20(9): 1596 - 1603. [Abstract] [Full Text] [PDF]

				L. Horn and A. Sandler Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Clin. Cancer Res., August 15, 2009; 15(16): 5040 - 5048. [Abstract] [Full Text] [PDF]

				M. A. Socinski, M. N. Saleh, D. F. Trent, T. W. Dobbs, L. M. Zehngebot, M. A. Levine, R. Bordoni, and P. J. Stella A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC) Ann. Onc., June 1, 2009; 20(6): 1068 - 1073. [Abstract] [Full Text] [PDF]

				C. Gridelli, P. Maione, M. L. Ferrara, and A. Rossi Cetuximab and Other Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer Oncologist, June 1, 2009; 14(6): 601 - 611. [Abstract] [Full Text] [PDF]

				N. Yamamoto, Y. Yamada, Y. Fujiwara, K. Yamada, Y. Fujisaka, T. Shimizu, and T. Tamura Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors Jpn. J. Clin. Oncol., April 1, 2009; 39(4): 260 - 266. [Abstract] [Full Text] [PDF]

				D. A. Nikolova, I. A. Asangani, L. D. Nelson, D. P.M. Hughes, D. R. Siwak, G. B. Mills, A. Harms, E. Buchholz, L. R. Pilz, C. Manegold, et al. Cetuximab Attenuates Metastasis and u-PAR Expression in Non-Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity Cancer Res., March 15, 2009; 69(6): 2461 - 2470. [Abstract] [Full Text] [PDF]

				D. D. Ruysscher, A. Botterweck, M. Dirx, M. Pijls-Johannesma, R. Wanders, M. Hochstenbag, A.-M. C. Dingemans, G. Bootsma, W. Geraedts, J. Simons, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study Ann. Onc., January 1, 2009; 20(1): 98 - 102. [Abstract] [Full Text] [PDF]

				M. A. Socinski What Guides Decisions about the Use of Epidermal Growth Factor Receptor Antibody or Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer? ASCO Educational Book, January 1, 2009; 2009(1): 436 - 443. [Abstract] [Full Text] [PDF]

				K. Yonesaka, K. Zejnullahu, N. Lindeman, A. J. Homes, D. M. Jackman, F. Zhao, A. M. Rogers, B. E. Johnson, and P. A. Janne Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers Clin. Cancer Res., November 1, 2008; 14(21): 6963 - 6973. [Abstract] [Full Text] [PDF]

				R. S. Herbst and A. Sandler Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC Oncologist, November 1, 2008; 13(11): 1166 - 1176. [Abstract] [Full Text] [PDF]

				F. R. Hirsch, R. S. Herbst, C. Olsen, K. Chansky, J. Crowley, K. Kelly, W. A. Franklin, P. A. Bunn Jr, M. Varella-Garcia, and D. R. Gandara Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non-Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy J. Clin. Oncol., July 10, 2008; 26(20): 3351 - 3357. [Abstract] [Full Text] [PDF]

				P. S. Hodkinson, A. MacKinnon, and T. Sethi Targeting Growth Factors in Lung Cancer Chest, May 1, 2008; 133(5): 1209 - 1216. [Abstract] [Full Text] [PDF]

				R. Rosell, G. Robinet, A. Szczesna, R. Ramlau, M. Constenla, B. C. Mennecier, W. Pfeifer, K. J. O'Byrne, T. Welte, R. Kolb, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer Ann. Onc., February 1, 2008; 19(2): 362 - 369. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe and M. A. Socinski Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer Oncologist, January 1, 2008; 13(suppl_1): 28 - 36. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr. and N. Thatcher Conclusion Oncologist, January 1, 2008; 13(suppl_1): 37 - 46. [Abstract] [Full Text] [PDF]

				C. A. Butts, D. Bodkin, E. L. Middleman, C. W. Englund, D. Ellison, Y. Alam, H. Kreisman, P. Graze, J. Maher, H. J. Ross, et al. Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer J. Clin. Oncol., December 20, 2007; 25(36): 5777 - 5784. [Abstract] [Full Text] [PDF]

				D. Morgensztern and R. Govindan Is There a Role for Cetuximab in Non Small Cell Lung Cancer? Clin. Cancer Res., August 1, 2007; 13(15): 4602s - 4605s. [Abstract] [Full Text] [PDF]

				M. V. Karamouzis, J. R. Grandis, and A. Argiris Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas JAMA, July 4, 2007; 298(1): 70 - 82. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr Can Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Be Overcome by Different Small-Molecule Tyrosine Kinase Inhibitors? J. Clin. Oncol., June 20, 2007; 25(18): 2504 - 2505. [Full Text] [PDF]

				B. C. Cho, C.-K. Im, M.-S. Park, S. K. Kim, J. Chang, J. P. Park, H. J. Choi, Y. J. Kim, S.-J. Shin, J. H. Sohn, et al. Phase II Study of Erlotinib in Advanced Non-Small-Cell Lung Cancer After Failure of Gefitinib J. Clin. Oncol., June 20, 2007; 25(18): 2528 - 2533. [Abstract] [Full Text] [PDF]

				P. Steiner, C. Joynes, R. Bassi, S. Wang, J. R. Tonra, Y. R. Hadari, and D. J. Hicklin Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor Clin. Cancer Res., March 1, 2007; 13(5): 1540 - 1551. [Abstract] [Full Text] [PDF]